XPose Therapeutics and Accelero Biostructures announce Joint Research Collaboration for the Discovery and Development of Novel Cancer Therapies
Share Article
Hit bound to target from fragment library screening
We use extensive training with pioneering experience in drug discovery; crystallography and structural biochemistry; and biology of DNA-binding and DNA repair proteins to a pipeline of DDR therapeutics SAN CARLOS, Calif. (PRWEB) December 22, 2020 XPose Therapeutics, Inc. (XPose) is excited to announce research agreements spanning multiple DNA Damage Response (DDR) targets for drug discovery using Accelero Biostructures, Inc. (Accelero) novel ABS-OneStep platform for hit generation and Accelero’s ABS-Services for iterative structure-guided optimization, both using high-throughput protein X-ray crystallography. ABS-OneStep handles fragment library screening directly by crystallography using the ABS-Real fr